Mohammad Haque
Memorial Sloan Kettering Cancer Center
2 Papers
7 Citations
Mohammad Haque is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Gene & Cancer. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS.
A. Rose Brannon,Gowtham Jayakumaran,Monica Diosdado,Juber Patel,Anna Razumova,Yu Hu,Fanli Meng,Mohammad Haque,Justyna Sadowska,Brian J. Murphy,Tessara Baldi,Ian Johnson,Ryan Ptashkin,Maysun Hasan,Preethi Srinivasan,Anoop Balakrishnan Rema,Ivelise Rijo,Aaron Agarunov,Helen Won,Dilmi Perera,David N Brown,Aliaksandra Samoila,Xiaohong Jing,Erika Gedvilaite,Julie L. Yang,Dennis Stephens,Jenna-Marie Dix,Nicole DeGroat,Khedoudja Nafa,Aijazuddin Syed,Alan Li,Emily S. Lebow,Anita S. Bowman,Donna C. Ferguson,Ying Liu,Douglas A. Mata,Rohit Sharma,Soo-Ryum Yang,Tejus Bale,Jamal Benhamida,Jason C. Chang,Snjezana Dogan,Meera Hameed,Jaclyn F. Hechtman,Christine Moung,Dara S. Ross,Efsevia Vakiani,Chad M. Vanderbilt,Jinjuan Yao,Pedram Razavi,Lillian M. Smyth,Sarat Chandarlapaty,Gopa Iyer,Wassim Abida,James J. Harding,Benjamin A. Krantz,Eileen M. O'Reilly,Helena A. Yu,Bob T. Li,Charles M. Rudin,Luis A. Diaz,David B. Solit,Maria E. Arcila,Marc Ladanyi,Brian Loomis,Dana W.Y. Tsui,Michael F. Berger,Ahmet Zehir,Ryma Benayed +68 more
TL;DR: MSK-ACCESS as mentioned in this paper is an NGS assay for detection of very low frequency somatic alterations in 129 genes and achieved 92% sensitivity in de-novo mutation calling down to 0.5% allele frequency and 99% for a priori mutation profiling.
Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assay
Angela Rose Brannon,Gowtham Jayakumaran,Monica Diosdado,Juber Patel,Anna Razumova,Yu Hu,Fanli Meng,Mohammad Haque,Justyna Sadowska,Brian J. Murphy,Tessara Baldi,Ian Johnson,Ryan Ptashkin,Maysun Hasan,Preethi Srinivasan,Anoop Balakrishnan Rema,Ivelise Rijo,Aaron Agarunov,Helen Won,Dilmi Perera,David N Brown,Aliaksandra Samoila,Xiaohong Jing,Erika Gedvilaite,Julie L. Yang,Dennis Stephens,Jenna-Marie Dix,Nicole DeGroat,Khedoudja Nafa,Aijazuddin Syed,Alan Li,Emily S. Lebow,Anita S. Bowman,Donna C. Ferguson,Ying Liu,Douglas A. Mata,Rohit Sharma,Soo-Ryum Yang,Tejus Bale,Jamal Benhamida,Jason C. Chang,Snjezana Dogan,Meera Hameed,Jaclyn F. Hechtman,Christine Moung,Dara S. Ross,Efsevia Vakiani,Chad M. Vanderbilt,JinJuan Yao,Pedram Razavi,Lillian M. Smyth,Sarat Chandarlapaty,Gopa Iyer,Wassim Abida,James J. Harding,Benjamin A. Krantz,Eileen M. O'Reilly,Helena A. Yu,Bob T. Li,Charles M. Rudin,Luis A. Diaz,David B. Solit,Maria E. Arcila,Marc Ladanyi,Brian Houck-Loomis,Dana Tsui,Michael F. Berger,Ahmet Zehir,Ryma Benayed +68 more
TL;DR: The experience illustrates the importance of analyzing a matched normal sample when interpreting cfDNA results and highlights the potential of cfDNA profiling to guide treatment selection, monitor treatment response, and identify mechanisms of treatment resistance.